Searchable abstracts of presentations at key conferences in endocrinology

ea0041oc5.3 | Neuroendocrinology | ECE2016

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Wilkinson Ian , Pradhananga Sarbendra , Speak Rowena , Sayers Jon , Ross Richard

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). We have developed a fusion technology for making a cost-effective long-acting GH molecule (3), and generated a GHA by linking mutated growth hormone to its binding protein (GHBP).<p class="abstext"...

ea0038oc2.4 | Translational pathophysiology and therapeutics | SFEBES2015

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Speak Rowena , Pradhananga Sarbendra , Justice Sue , Ross Richard , Wilkinson Ian

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). This is because many patients do not respond to somatostatin therapy. Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). There is therefore an unmet need for a cost-effective GHA. We have developed a fusion technology for making a cost-effective long-a...

ea0035p825 | Paediatric endocrinology | ECE2014

Medication safety study investigating hydrocortisone individually and extemporaneously compounded capsules for paediatric use in congenital adrenal hyperplasia

Kauzor Daniela , Spielmann Sarah , Ross Richard , Blankenstein Oliver , Kloft Charlotte

Background: Treatment outcome with hydrocortisone for congenital adrenal hyperplasia (CAH) in neonates and children is highly variable. As there is no licensed formulation for children <6 years hydrocortisone capsules individually have to be compounded by local pharmacies (dose strength: 0.5–9.5 mg). The aim of this study was to characterise mass and content of these capsules in order to assess medication safety for effective and nontoxic dosing in terms of precision ...

ea0034oc5.6 | Pituitary | SFEBES2014

A GH antagonist fusion with GH binding protein is biologically active, shows delayed clearance and inhibits growth in a rabbit model

Wilkinson Ian , Phipps Michael , Sayers Jon , Artymiuk Peter , Ross Richard

Background: Acromegaly is associated with increased morbidity and mortality, however currect medical treatment controls the disease in <60% of patients. Pegvisomant, a pegylated GH antagonist, controls the disease in over 95% of cases, but is not cost effective as it requires high dose daily injections and has side-effects. We have developed a technology for generating a long acting potent GH antagonist.Hypothesis: That a GH antagonist fused to GH bi...

ea0015p188 | Endocrine tumours and neoplasia | SFEBES2008

Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide

Debono Miguel , Bridgewater Caroline , Ross Richard , Price John Newell

Background: Prolactinomas are usually highly sensitive to dopamine agonists. We report the use of temozolomide in a 47-year-old gentleman with MEN 1 and a highly dopamine agonist-resistant, and aggressive prolactinoma.Case summary: He presented in 2001 with a 3rd nerve palsy and recurrent headaches. MRI revealed a pituitary tumour extending into the left cavernous sinus. Prolactin levels were 29 000 mU/l. (NR<360). Primary hyperparathyroidism, a lesi...

ea0015p202 | Growth and development | SFEBES2008

Attempted detection of recombinant glycosylphosphatidylinositol-anchored proteins using Fluorescently Labelled Aerolysin, FLAER

Kaabi Yahia , Wilkinson Ian , Richards Gareth , Skerry Tim , Ross Richard

Introduction: Glycosylphosphatidylinositol (GPI) anchored proteins are common on the surfaces of eukaryotic cells. An example is alkaline phosphatase. Fluorescently Labelled Aerolysin (FLAER) is a bacterial toxin produced by the gram-negative bacterium Aeromonas hydrophila that binds naturally to GPI anchored proteins and utilizes them as receptors to cause cytotoxicity. FLAER has been used to discriminate the GPI deficient red blood cells in cases of paroxysmal nocturn...

ea0085p47 | Adrenal 2 | BSPED2022

Salivary sampling in neonates, infants, and young children: glucocorticoid stability under different conditions and the introduction of a novel collection technique

Tonge Joseph , Keevil Brian , Craig Jessica , Whitaker Martin , Ross Richard , Elder Charlotte

Background: Measurement of salivary glucocorticoids is gaining popularity as it offers a non-invasive collection technique, enabling sampling in the community or home environment, allowing tailored capture of steroid circadian rhythm and improved patient experience. Current popular salivary collection methods cannot be used in very young children due to choking and the requirement for active participation. There is little data on saliva stability during home collection.<p ...

ea0090p557 | Adrenal and Cardiovascular Endocrinology | ECE2023

Retrospective study of steroid weaning in tertiary adrenal insufficiency comparing prednisolone and hydrocortisone

Fahad Arshad Muhammad , Elder Charlotte , Newell-Price John , Ross Richard , Debono Miguel

Background: The hypothalamic-pituitary-adrenal (HPA) axis can be suppressed by long-term exogenous glucocorticoids, resulting in tertiary adrenal insufficiency (AI). International expert consensus suggests that during weaning, prednisolone be converted to hydrocortisone to allow HPA axis reactivation(1). There is, however, little evidence to support this practice.Aim: To compare HPA axis recovery during treatment with prednisolone and immediat...

ea0048cp5 | Poster Presentations | SFEEU2017

Pasireotide: successful treatment of a resistant case of Acromegaly

Liyanarachchi Kamani , Amarawardena Maheshi , Newell-Price John , Ross Richard , Debono Miguel

Case history: A 26 year old lady presented in 1999 with a 3 year history of worsening headache, increased sweating, excessive tiredness and progressive enlargement of hands and feet. She was otherwise well and had no family history of pituitary tumors, hypercalcaemia or renal stones. On examination she had typical facial features of acromegaly and acral enlargement. Her blood pressure was normal and visual fields were full.Investigations: Oral Glucose To...

ea0038p205 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study

Greenfield Diana , Blewitt Alice , Coleman Robert , Walsh Jennifer , Snowden John , Ross Richard , Han Thang

Background: Life expectancy of cancer survivors has doubled in the past four decades; however, death due to cardiovascular disease is more prevalent in survivors than the general population.Objective, design and methods: We evaluated novel and traditional cardiometabolic risk factors in young male cancer survivors in a cross-sectional study of male cancer survivors aged 25–45 years compared with age-matched non-cancer controls. Demographic and anthr...